CD19 CAR-T cell immunotherapy / Lonza, Sheba Medical Center - LARVOL DELTA

Lonza and Sheba Medical Center Use Cocoon Platform and Show Successful Clinical Outcomes in Patients Treated with CAR-T Cell Immunotherapy (Lonza) - P=NA, N=4; "Sheba Medical Center at Tel Hashomer...announced today that they have treated multiple patients with CD19 CAR-T cell immunotherapy targeting B-cell malignancies. Three patients have shown complete responses, and another patient is still being evaluated...All patients were dosed with therapies manufactured in Lonza’s Cocoon® Platform, an automated, customizable, patient-scale cell therapy platform that streamlines manufacturing to improve process efficiency and reliability."

Clinical data • Trial status • Hematological Malignancies • Oncology

Lonza Says First Lymphoma Patient Dosed With CAR-T Made In 'Cocoon' System (Reuters) - "Lonza said on Tuesday the first patient has been treated with a cell therapy made in its 'Cocoon' platform, which the Swiss contract drug maker hopes catches on at medical centers aiming to boost use of personalized cancer treatments...The first patient treated with Sheba's CAR-T from the Cocoon has diffuse large B cell lymphoma (DLBCL)."

Enrollment status • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Oncology